The initial theory behind the creation of these medications was to take advantage of the body’s renal glucose management by decreasing SGLT2-mediated glucose reabsorption from the proximal renal tubule, causing glycosuria and controlling hyperglycemia [51]. This evidence concerns the gene SLC5A2 and Hyperglycemia.